US Stock Insider Trading | TransMedics Group disclosed three insider trading transactions on March 6

K-LinePoet · 2026-03-07T00:17:05+00:00

On March 6, 2026, TransMedics Group disclosed insider trading activity, with Director Weill David selling 3,571 shares on March 4, while executive Hernandez Gerardo engaged in multiple buy and sell transactions, reflecting active trading of the company's executives in the stock.

K-LinePoet

2026-03-07 00:17:05

Abstract generation in progress

On March 6, 2026, TransMedics Group (TMDX) disclosed three insider transactions. Director Weill David sold 3,571 shares on March 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 6, 2026	Director	Weill David	March 4, 2026	Buy	3,571	14.20	$50,700
March 6, 2026	Director	Weill David	March 4, 2026	Sell	3,571	146.82	$524,300
March 6, 2026	Director	Lovell Stephanie	March 4, 2026	Sell	1,193	149.62	$178,500
March 4, 2026	Executive	Hernandez Gerardo	March 4, 2026	Buy	1,324	77.12	$102,100
March 4, 2026	Executive	Hernandez Gerardo	March 4, 2026	Buy	5,912	69.84	$412,900
March 4, 2026	Executive	Ranganath Anil P.	March 2, 2026	Sell	864	139.12	$120,200
March 4, 2026	Executive	Hernandez Gerardo	March 4, 2026	Sell	7,236	147.21	$1,065,200
March 4, 2026	Executive	Hernandez Gerardo	March 2, 2026	Sell	375	139.12	$52,200
January 23, 2026	Executive	Corcoran Nicholas	January 23, 2026	Sell	984	135.30	$133,100
March 2, 2026	Executive	Corcoran Nicholas	March 2, 2026	Sell	2,966	139.12	$412,600

[Company Information]

TransMedics Group, Inc. was incorporated in August 1998. The company is a commercial-stage medical technology firm that provides organ transplant treatments for patients with end-stage organ failure due to various diseases. The company has developed a perfusion system to replace decades-old standards of care. This innovative perfusion technology replicates many aspects of the natural living and functional environment of organs outside the body. OCS represents a shift in the approach, transforming static organ preservation into a dynamic environment, enabling new functions such as organ optimization and assessment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.